Your browser is no longer supported. Please, upgrade your browser.
CEMI Chembio Diagnostics, Inc. monthly Stock Chart
CEMI [NASD]
Chembio Diagnostics, Inc.
Index- P/E- EPS (ttm)-1.16 Insider Own19.10% Shs Outstand18.87M Perf Week1.65%
Market Cap99.78M Forward P/E- EPS next Y-0.56 Insider Trans0.00% Shs Float17.36M Perf Month18.23%
Income-20.50M PEG- EPS next Q-0.26 Inst Own43.00% Short Float25.89% Perf Quarter-6.98%
Sales28.50M P/S3.50 EPS this Y-48.00% Inst Trans-1.38% Short Ratio1.32 Perf Half Y-61.69%
Book/sh2.05 P/B2.40 EPS next Y53.30% ROA-33.90% Target Price5.00 Perf Year-8.70%
Cash/sh1.80 P/C2.74 EPS next 5Y25.00% ROE-76.90% 52W Range2.25 - 15.89 Perf YTD8.11%
Dividend- P/FCF- EPS past 5Y-46.60% ROI-30.50% 52W High-68.97% Beta2.12
Dividend %- Quick Ratio2.80 Sales past 5Y4.50% Gross Margin26.50% 52W Low119.11% ATR0.28
Employees295 Current Ratio3.80 Sales Q/Q-48.50% Oper. Margin-65.00% RSI (14)53.11 Volatility3.85% 6.24%
OptionableYes Debt/Eq0.47 EPS Q/Q-120.70% Profit Margin-71.90% Rel Volume0.24 Prev Close4.95
ShortableYes LT Debt/Eq0.47 EarningsNov 05 AMC Payout- Avg Volume3.41M Price4.93
Recom3.00 SMA200.78% SMA506.46% SMA200-18.27% Volume824,454 Change-0.40%
Jun-17-20Downgrade The Benchmark Company Speculative Buy → Hold
Jun-17-20Downgrade Craig Hallum Buy → Hold
Jun-17-20Downgrade Canaccord Genuity Buy → Hold $7
May-26-20Initiated Robert W. Baird Outperform $21
Mar-04-20Reiterated The Benchmark Company Speculative Buy $9 → $6
Mar-04-20Reiterated The Benchmark Company Speculative Buy $9 → $5
Dec-19-18Initiated Dougherty & Company Buy
Aug-11-16Reiterated The Benchmark Company Speculative Buy $10 → $9
Apr-18-16Reiterated The Benchmark Company Speculative Buy $6 → $8
Nov-04-15Initiated The Benchmark Company Speculative Buy $6
Sep-10-13Resumed The Benchmark Company Speculative Buy $7
Oct-23-20 08:00AM  
Oct-16-20 07:15AM  
Oct-15-20 05:55PM  
Oct-06-20 08:38AM  
Oct-02-20 10:10AM  
07:26AM  
Sep-25-20 08:55AM  
Sep-08-20 06:00PM  
Aug-25-20 08:57AM  
Aug-17-20 02:15PM  
11:50AM  
11:40AM  
11:01AM  
07:30AM  
06:55AM  
Aug-16-20 03:09PM  
11:44AM  
10:51AM  
Aug-15-20 02:35PM  
Aug-14-20 03:55PM  
02:25PM  
01:00PM  
12:00PM  
10:00AM  
09:31AM  
08:30AM  
Aug-13-20 07:40PM  
06:10PM  
02:25PM  
01:45PM  
12:45PM  
11:31AM  
10:30AM  
09:47AM  
Aug-12-20 04:45PM  
04:11PM  
04:10PM  
03:27PM  
03:15PM  
02:40PM  
12:35PM  
11:59AM  
09:26AM  
Aug-11-20 07:15PM  
11:00AM  
Aug-10-20 10:01PM  
08:35PM  
07:42PM  
06:11PM  
03:05PM  
01:59PM  
01:35PM  
12:50PM  
12:38PM  
11:30AM  
06:20AM  
Aug-08-20 08:01PM  
Aug-07-20 08:24PM  
07:13PM  
02:15PM  
01:15PM  
Aug-06-20 04:10PM  
04:05PM  
12:15PM  
11:09AM  
06:20AM  
Aug-05-20 11:58PM  
03:35PM  
11:30AM  
06:20AM  
Aug-04-20 01:26PM  
11:30AM  
10:16AM  
08:30AM  
Aug-03-20 09:58PM  
08:15PM  
05:45PM  
05:21PM  
06:35AM  
Aug-02-20 10:05AM  
Aug-01-20 06:45PM  
Jul-31-20 04:40PM  
03:15PM  
01:50PM  
01:21PM  
12:45PM  
Jul-30-20 03:35PM  
02:25PM  
02:25PM  
Jul-29-20 11:00PM  
09:10PM  
02:40PM  
Jul-28-20 09:15PM  
08:20PM  
12:40PM  
06:30AM  
Jul-27-20 10:00PM  
09:15PM  
03:35PM  
10:50AM  
Chembio Diagnostics, Inc., together with its subsidiaries, develops, manufactures, and commercializes point-of-care (POC) diagnostic tests that are used to detect or diagnose diseases. The company offers tests for HIV and Syphilis, and Zika virus. It also develops tests for malaria, Dengue virus, chikungunya virus, ebola, lassa, marburg, leptospirosis, Rickettsia typhi, Burkholderia pseudomallei, and Orientia tsutsugamushi. In addition, the company develops tests for a specific form of cancer, concussion, and bovine tuberculosis; and handheld optical analyzers for rapid diagnostic tests. It sells its products under the STAT-PAK, SURE CHECK, STAT VIEW, or DPP trademarks, as well as under the private labels of its marketing partners to medical laboratories and hospitals, governmental and public health entities, non-governmental organizations, medical professionals, and retail establishments in the United States and internationally. The company has collaboration agreements with Concussion Science Group Division of Perseus Science Group LLC to develop a POC diagnostic test for traumatic brain injury; Foundation for Innovative New Diagnostics to develop a POC fever panel assay for life-threatening acute febrile illnesses; AstraZeneca to develop a POC test for eosinophilic respiratory disease; and Shire Human Genetic Therapies, Inc. to develop a novel POC diagnostic test. It also has a strategic partnership with LumiraDx Limited to develop point-of-care diagnostic tests for the detection of the COVID-19 virus, and IgM and IgG antibodies on the LumiraDx and Chembio DPP platforms. Chembio Diagnostics, Inc. was founded in 1985 and is headquartered in Hauppauge, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Potthoff John GaryDirectorNov 11Buy4.4410,00044,40037,772Nov 13 07:21 PM
affiliate | advertise | contact | privacy | help
Do not sell my personal information

Quotes delayed 15 minutes for NASDAQ, and 20 minutes for NYSE and AMEX.
Copyright © 2007-2020 FINVIZ.com. All Rights Reserved.